Drug Treatment of Patients with Insomnia and Excessive Daytime Sleepiness
- 1 January 1999
- journal article
- review article
- Published by Springer Science and Business Media LLC in Clinical Pharmacokinetics
- Vol. 37 (4), 305-330
- https://doi.org/10.2165/00003088-199937040-00003
Abstract
Insomnia and excessive daytime sleepiness (EDS) are frequently observed conditions in the general public. A national survey in the USA in 1979 indicated that 35% of American adults experience insomnia in the course of a year. The prevalence of EDS varies depending on the survey (0.3 to 13.3%), but a recent study stated that 2.4% of individuals reported that they continually fell asleep at work. These problems are often long term and negatively affect the individuals' quality of life. People with these sleep problems often have difficulties maintaining high levels of productivity at work or pursuing their daily activities; individuals with insomnia lack the feeling of being rested or refreshed in the morning and EDS is unavoidable in most cases. Behavioural therapy has been shown to be effective for many people affected with insomnia and EDS. However, pharmacological treatments using hypnosedatives and central nervous system (CNS) stimulants are usually necessary, and effective, for those with more severe cases. These compounds have thus been widely prescribed in clinical practice (e.g., 2.6% of all adults surveyed used medically prescribed hypnosedatives and 4.5% used over-the-counter drugs to promote sleep). The onset and duration of action of these hypnosedatives and CNS stimulant drugs are important factors to be considered when prescribing these compounds. These factors primarily depend on physicochemical properties (lipid solubility and protein binding), as well as the pharmacokinetic profile (absorption, distribution, elimination and clearance) of the compounds. Significant differences in profile exist amongst hypnosedatives and CNS stimulants, and these differences may account for the observed variations in clinical action and adverse effects during and after treatment. In this review, we will introduce recently obtained knowledge of the pharmacokinetics of hypnosedatives and CNS stimulants and their applications for patients affected with insomnia and EDS.Keywords
This publication has 97 references indexed in Scilit:
- Effects of Modafinil on Symptomatology of Human NarcolepsyClinical Neuropharmacology, 1993
- NarcolepsyJournal Of Clinical Neurophysiology, 1990
- Gamma-hydroxybutyrate, a possible neurotransmitterLife Sciences, 1987
- Therapy for Sleep Disorders in DepressivesPsychopathology, 1986
- Problems and Coping Strategies Identified by Narcoleptic PatientsJournal of Neuroscience Nursing, 1984
- A Comparative 25‐Night Sleep Laboratory Study on the Effects of Quazepam and Triazolam on Chronic InsomniacsThe Journal of Clinical Pharmacology, 1984
- Psychotropic drugs and accidents in a general practice.BMJ, 1983
- Early Morning Insomnia with Rapidly Eliminated BenzodiazepinesScience, 1983
- Catecholamines and the sleep-wake cycle I. EEG and behavioral arousalLife Sciences, 1982
- Electroencephalographic analyses of amphetamine and its methoxy derivatives with reference to their sites of EEG alerting in the rabbit brainInternational Journal of Neuropharmacology, 1969